DarioHealth completes $15.4M preferred stock placement and $30M credit facility refinancing

On May 1, 2023, the Company filed the Series B Certificate of Designation, designating 30,000 shares of Series B Preferred Stock, the Series B-1 Certificate of Designation, designating 15,000 shares of Series B-1 Preferred Stock, and the Series B-2 Certificate of Designation, designating 15,000 shares of Series B-2 Preferred Stock in connection with the Offering. On May 5, 2023, the Company filed the Series B-3 Certificate of Designation, designating 15,000 shares of Series B-3 Preferred Stock in connection with the Offering.

On May 1, 2023, DarioHealth Corp. (the "Company") entered into securities purchase agreements (each, a "Series B Purchase Agreement") with accredited investors relating to an offering (the "Offering") and the sale of an aggregate of 6,200 shares of newly designated Series B Preferred Stock (the "Series B Preferred Stock"), an aggregate of 7,946 shares of Series B-1 Preferred Stock (the "Series B-1 Preferred Stock"), and an aggregate of 150 shares of Series B-2 Preferred Stock (the "Series B-2 Preferred Stock") at a purchase price of $1,000 for each share of Preferred Stock.

On May 5, 2023, the Company entered into purchase agreements (the "Series B-3 Purchase Agreement" and together with the Series B Purchase Agreement, the "Purchase Agreement") with accredited investors, relating to the Offering, to an offering and the sale of an aggregate of 1,106 shares of newly designated Series B-3 Preferred Stock (the "Series B-3 Preferred Stock" and, collectively with the Series B Preferred Stock, the Series B-1 Preferred Stock and the Series B-2 Preferred Stock, the "Preferred Stock"), at a purchase price of $1,000 for each share of Preferred Stock.